AG
Therapeutic Areas
Scholar Rock Holding Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Apitegromab (SRK-015) | Spinal Muscular Atrophy (SMA) | Phase 3 |
| SRK-181 | Solid Tumors (Anti-PD-1 Resistant) | Phase 1/2 |
| SRK-439 | Obesity / Muscle Atrophy | Preclinical |
Leadership Team at Scholar Rock Holding
JB
Jay Backstrom
President & Chief Executive Officer
TM
Ted Myles
Chief Financial Officer & Head of Business Operations
YC
Yung Chyung
Chief Medical Officer
DH
David Hallal
Chairman of the Board
TA
Timothy A. Springer
Founder & Chair of Scientific Advisory Board
MQ
Mo Qatanani
Chief Scientific Officer
LW
Luhua Wang
Senior Vice President, Discovery & Translational Sciences
SB
Sasha B. Moghaddam
Senior Vice President, General Counsel
MC
Matthew C. Frankel
Senior Vice President, Corporate Development & Strategy
NM
Nagesh Mahanthappa
Board Member